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of other materials as well as scaffolds, 
for example, for tissue regeneration are 
among the most promising strategies to 
prevent microbial colonization.[5] Unfor-
tunately, the emergence of drug-resistant 
strains as well as the insufficient activity 
or concentration of antibiotics at the site 
of infection lead to their failure in clinical 
treatment.[6,7] Different strategies have 
been developed to achieve a long-term 
antibiotic therapy, such as chemical modi-
fication of antibiotics, development of new 
antimicrobial agents, and new formula-
tion methods for antibiotic delivery.[8–11] 
Nanomaterials can also be used in drug 
formulations, enabling the development 
of targeted delivery systems to the site of infection, minimizing 
nonspecific interactions, and controlling delivery of antibiotics 
mitigating the development of microbial resistance and other 
side effects experienced with traditional therapies.[10,12–15] Nano-
carriers also allowed combination therapy with multi-antibiotics 
delivery and flexibility of the dosage amount.[16,17]
In the last decade, mesoporous silica nanoparticles (MSN) 
have been explored as nanovehicles for delivery of antibiotics 
and other drugs due to several advantageous properties, such 
as a high surface area, large pore volume, tunable particle and 
pore size, and easy surface functionalization.[18–20] Using MSN, 
antibiotic delivery systems have been prepared through various 
techniques, for example, functionalized or adsorbed antimicro-
bials on the surface, encapsulating the active molecule within 
the nanoparticles, chemically conjugating antimicrobiotics 
to particles surface, and depositing drugs using layer-by-layer 
(LbL) assembly.[14,19]
Here, we designed enhanced antimicrobial composite 
materials for sustainable drug release to combat bacterial 
and fungal infections by combining the engineered spider 
silk protein eADF4(C16) and antimicrobials loaded MSN. 
eADF4(C16) is a recombinant spider silk protein based on 
the consensus sequence of the core domain of Araneus dia-
dematus fibroin 4 (ADF4) of the dragline silk of the European 
garden spider A. diadematus.[21] eADF4C(16)-based mate-
rials present interesting properties such as biocompatibility, 
absence of toxicity, low/non-immune reactivity, and controlled 
biodegradability.[22–24] Furthermore, eADF4(C16) can be fabri-
cated into different morphologies like films,[25,26] non-woven 
mats,[27] hydrogels,[28] foams,[29] and bioinks,[30] and can be 
used as coating materials for implants[31,32] and other biomed-
ical products.[26]
The utilization of spider silk–MSN composites as antimi-
crobial materials were demonstrated by encapsulating a variety 
of aminoglycoside antibiotics and antimycotics as shown in 
Fabricating biomaterials with antimicrobial activity to prevent the growth of det-
rimental microorganisms is of great scientific and practical interest. Here, com-
posite materials comprising recombinant spider silk proteins and mesoporous 
silica nanoparticles (MSN) loaded with selected antibiotics and antimycotics 
are fabricated into films and hydrogels. The derived composite materials exhibit 
excellent antimicrobial properties with sustained release of antibiotics over the 
course of 15 days. Furthermore, antibiotics/antimycotics inclusion does not 
impair the cytocompatibility of the composite materials, all of which promote 
fibroblast cell adhesion and proliferation. Finally, processing of spider silk–MSN 
composite hydrogels using 3D printing is shown to enable the fabrication of 
patient-specific antimicrobial implants to prevent infection in the near future.
Antimicrobial modification of surfaces to inhibit bacterial or 
fungal colonization is a highly desired objective in medicine. 
Microbial attachment and subsequent microbial colonization as 
well as biofilm formation on surfaces, for example, of medical 
equipment, leads to the transmission of community-acquired 
or hospital-acquired (nosocomial) infections deteriorating 
public health and impeding healthcare, cosmetics and tech-
nical applications.[1,2] Bacterial infections based on biomedical 
implants and devices are one of the growing problems leading 
to the failure of implants and promoting the chances of revi-
sion surgery.[3,4]
Antibiotics are widely used as a treatment to cure micro-
bial infections, and their incorporation into films for coating 
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Scheme 1. The spider silk–MSN (SM) composite films were 
further used to coat polymeric, metallic, as well as ceramic 
materials to show their efficacy in killing bacteria and fungi. 
Selected antibiotics, namely gentamicin (G), kanamycin (K), 
and neomycin (N), and the antimycotic amphotericin B (A), 
possess biologic activities rendering them successful disinfect-
ants, antiseptic and anti-inflammatory agents. Antibiotic activity 
of the SM composites was evaluated based on the growth inhi-
bition of Escherichia coli (E. coli) and Pichia pastoris (P. pastoris). 
SM composites showed excellent performance in terms of anti-
microbial properties including their minimum inhibitory con-
centrations (MICs) and surface antimicrobial activities against 
E. coli and P. pastoris.
Spherical MSN with a particle size of 72 ± 5 nm were syn-
thesized through a sol–gel process and characterized using 
scanning electron microscopy (SEM) and transmission electron 
microscopy (TEM), Figure S1, Supporting Information.[33,34] 
MSN were loaded with aminoglycoside antibiotics (gentamicin, 
neomycin, and kanamycin) and antimycotics (Amphotericin 
B) dissolved in Tris buffer (10 mm, pH 7.5) via diffusion upon 
incubation for 24 h at 37 °C. Loading of antibiotics onto silica 
particles is highly favorable as aminoglycoside antibiotics/
antimycotics contain a hydroxyl as well as secondary amine 
groups, initiating supramolecular interactions between the 
drug and silica matrices (electrostatic interactions, hydrogen 
bonding, л–л stacking, etc.). The loading amount was calcu-
lated to be 400 µg gentamicin (G), 350 µg neomycin (N), 390 µg 
kanamycin (K), and 6.2 µg Amphotericin B (A) per mg MSN, 
respectively, Figure S2, Supporting Information.
Antibiotics and antimycotics loaded MSN were mixed with 
4% w/v recombinant spider silk solution, and composite films 
were made by drop casting followed by post-treatment with 
ethanol. The presence of silica nanoparticles in the spider silk 
matrix was confirmed SEM, atomic force microscopy (AFM), 
and Fourier transform infrared (FT-IR) spectroscopy, as shown 
in Figure 1a,b; Figure S3, Supporting Information. Minimum 
inhibitory concentrations (MICs) of the antibiotics/antimy-
cotics loaded SM composite films were evaluated using liquid 
cultures of E. coli and P. pastoris, respectively. After 24 h, the 
optical density at 600 nm (OD600) of the bacterial/yeast cell sus-
pension in contact with the film showed a significant decline 
in the bacterial and yeast cell growth with increasing concen-
tration of antibiotics/antimycotics loaded MSN particles in the 
composite films, Figure 1c,d. Therefore, SM composite films 
with sufficient drug concentrations are able to significantly 
suppress microbial growth in the surrounding solution.
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Scheme 1. Schematic representation of drug-loaded recombinant spider silk-mesoporous silica nanoparticles (MSN) composite films and hydrogels 
with anti-microbial properties.
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The antimicrobial properties of films and coatings were 
prepared using a 4% w/v eADF4(C16) solution mixed with 
0.5% w/v MSN loaded with antibiotics or antimycotic and 
were tested using a zone of inhibition test on agar plates. All 
free-standing silk–silica composite films of SM_G, SM_K, 
and SM_N were placed on E. coli-inoculated agar plates and 
SM_A films on P. pastoris-inoculated agar plates and incu-
bated for 12 h at 37 °C. Antimicrobial activity of the films 
could be seen as prominent zone of inhibition rings around 
films, Figure 1e–g,i. Significant inhibition zones with diam-
eters of 8–9 mm were observed for SM_G, SM_K, and SM_N, 
and 3 mm for SM_A. The smaller inhibition zone observed 
for SM_A is due to the very low solubility of Amphotericin B 
in water. Importantly, recombinant spider silk films without 
MSN did not have any detectable inhibition zone (Figure S4, 
Supporting Information) indicating that recombinant spider 
silk materials cannot actively reduce already existing infec-
tions. Next, we tested the ability of the SM composite films 
to serve as antibacterial coatings on other materials such as 
glass, aluminum (Al), and polydimethylsiloxane (PDMS), all 
processed by dip coating. SEM microscopy analysis depicted 
smooth and crack-free coatings on the materials surfaces 
(Figure S5, Supporting Information). Also, no bacterial growth 
was observed on top of the coatings or adjacent to the coatings 
(zone of inhibition) after 24 h incubation, Figure 1h. Coated 
surfaces resisted biofilm formation. Therefore, SM composite 
coatings can be used in the future to improve the efficacy of 
medical devices and implants.
To fabricate SM composite hydrogels, 1% w/v MSN loaded 
with antibiotics or antimycotic were added to aqueous solu-
tions of 4% w/v eADF4(C16) under static conditions, followed 
by gelation of the silk at 37 °C. The morphology of the MSN-
loaded freeze-dried eADF4(C16) hydrogel was investigated by 
SEM (Figure S6, Supporting Information). The time-dependent 
antimicrobial efficacy of SM composite hydrogels was tested 
using zone of inhibition tests against E. coli and P. pastoris 
Macromol. Rapid Commun. 2020, 41, 1900426
Figure 1. a) SEM images of eADF4(C16)_MSN (SM) films. b) Tapping mode atomic force microscopy images showing the topography of SM films on 
Si wafer. The average surface roughness Ra of 180 nm was calculated at an area of 9 µm2. c,d) Antibacterial/antifungal activity of antibiotics (gentamicin 
(G), kanamycin (K), neomycin (N)), and antimycotic (Amphotericin B (A)) loaded SM composite films in a concentration dependent manner. Turbidity 
of E. coli suspensions in Luria–Bertani (LB) medium at 37 °C and P. pastoris in yeast extract–peptone–dextrose (YPD) medium at 30 °C were measured 
at 600 nm (OD600) after 24 h incubation. The results are expressed as mean ± SD, and experiments were done in triplicate with a minimal sample 
number of three. e–h) Inhibition zone test of antimicrobial loaded SM films and film coated surfaces using E. coli on agar plates; e) SM_G free standing 
films; f) SM_K free standing films; g) SM_N free standing films, h) SM_G coated material surfaces (glass, Al and PDMS), and i) SM_A free-standing 
films using P. pastoris on an agar plate. Black dotted circles represent the inhibition zone area. Scale bars (e–i): 2 cm.
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on agar plates. Antimicrobials loaded SM hydrogels were first 
incubated in PBS (25 mm K-Phos, 100 mm NaCl, pH 7.5) for 
10 days and then removed to test their remaining antibacterial 
or antifungal properties on day 2, day 5, and day 10 on agar 
plates inoculated with bacteria or yeast, Figure 2a–l. Inhibi-
tion zones around SM composite hydrogels showed that the 
activity of antibiotics and antimycotics was retained within the 
hydrogels even after 10 days of incubation in PBS and demon-
strated its usability for long-term antimicrobial activity against 
microbial infection. Also, the in vitro release behavior of antibi-
otics from MSN embedded in 4% w/v eADF4(C16) hydrogels 
were analyzed in PBS. The release profile showed a slow and 
continuous release of antibiotics over 14 days, with a release of 
gentamicin, neomycin, and kanamycin of 34%, 29%, and 38%, 
(Figure S7, Supporting Information). The slow release of antibi-
otics suggested that silk–silica composite hydrogels can be used 
as a drug delivery system to achieve sustained release of drugs, 
and administering drugs systemically to avoid side effects due 
to high local concentrations.
To illustrate the versatility of this approach, recombinant SM 
composite hydrogels were 3D printed. The concept is demon-
strated in Figure 2m with 3D printed constructs using robotic 
dispensing of gentamicin loaded silk–silica (SM_G) composite 
hydrogels on an agar plate. Introduction of E. coli to the 3D 
printed constructs after printing resulted in a well-defined inhi-
bition zone demonstrating that the antibacterial activity was 
retained after printing. 3D printing of SM composites holds the 
potential toward fabrication of anti-infective scaffolds with inte-
grated drugs for biomedical applications.
A high dose of antibiotics might significantly interfere with 
cell replication and even cause cell death. Therefore, we studied 
the cytotoxicity of antimicrobial loaded spider silk–MSN 
films using fibroblasts, which are one of the first anchorage-
dependent cells to interact with an implant surface during 
the wound healing process. Recombinant spider silk protein 
eADF4(C16) lacks cell binding motifs, however, materials made 
of the genetically modified variant eADF4(C16)-RGD have 
shown high potential for tissue engineering applications.[29,30,35] 
Films and hydrogels made of eADF4(C16)-RGD have previ-
ously been thoroughly characterised, and studies showed no 
significant differences in their physicochemical properties as 
well as secondary structure in comparison to eADF4(C16).[35–37] 
The viability of BALB/3T3 cells was evaluated on films of 
eADF4(C16)-RGD with encapsulated antimicrobial loaded 
nano particles analysing their mitochondrial activity. No cyto-
toxicity could be detected, Figure 3a. In addition, proliferation 
was good on the respective films (Figure 3b,d–f) and within the 
hydrogels (Figure 3c,g–i).
Novel drug-eluting composite materials were prepared by 
combining recombinant spider silk eADF4(C16) and anti-
microbial agents loaded MSN to prevent biofilm formation. 
Spider silk–MSN (SM) composites films and hydrogels exhib-
ited long-lasting antimicrobial properties against E. coli and P. 
pastoris. In addition, the composites could be processed into 
coatings on glass, metals, and PDMS, and exhibited there 
also long-lasting antibacterial properties. Release profiles of 
antibiotics-loaded composite hydrogels demonstrated the pre-
served antibacterial potency over 2 weeks via sustained release 
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Figure 2. Inhibition zone test of antimicrobial loaded SM hydrogels using E. coli and P. pastoris on agar plates to show the sustainability of antimicrobial 
release. a–d) Hydrogels after 2 days of incubation in PBS: a) SM_G, b) SM_K, c) SM_N, and d) SM_A. Similarly, inhibition zone tests were performed 
for antimicrobial-loaded SM hydrogels after incubation in PBS on e–h) day 5 and i–l) day 10. 3D printing of (m) 4% w/v gentamicin (G) loaded SM_G 
hydrogel on an agar plate. After printing, E. coli bacteria culture (OD600 = 1.0) was spread on the plates and incubated overnight at 37 °C. The dotted 
rectangular area shows the inhibition zone for the growth of E. coli bacteria on the agar plate. Scale bars: 2 cm.
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of antibiotics. Furthermore, 3D printed SM composite hydro-
gels showed zones of inhibition upon direct contact with E. 
coli. Combining such SM composites with 3D printing ena-
bles fabrication of patient-specific antimicrobial implants to 
prevent infection. Additionally, the potential of drug-eluting 
SM composite scaffolds was revealed in the context of bio-
medical and wound healing processes. In summary, this study 
demonstrates putative applications for SM composites that 
may be used in various biomedical applications and as coat-
ings for surgical tools.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
Figure 3. a) Cell viability of mouse BALB/3T3 fibroblasts cultured on films of antimicrobial loaded eADF4(C16)-RGD_MSN (RM) films (antimicrobi-
otics concentration as indicated) was quantified using the Cell-titer blue assay after 48 h of incubation at 37 °C. Cell-viability was normalized with cells 
cultured on treated well plates (positive control). b,c) Proliferation of BALB/3T3 fibroblasts on films and hydrogels over 5 and 10 days, respectively, 
was quantified using the cell-titer blue assay. Live-dead cell microscopy of mouse BALB/3T3 fibroblasts cultivated on d–f) composite silk–silica films 
and g–i) composite silk–silica hydrogels. Scale bars: d–f) 100 µm and g–i) 250 µm. The cells were stained with calcein A/M (live cells: green) and 
ethidium homodimer I (dead cells: red). Ethidium homodimer I also stained the hydrogels yielding an unspecific red background fluorescence (g–i).
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